

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT SEATTLE

PHARMACEUTICAL RESEARCH AND  
MANUFACTURERS OF AMERICA;  
GENERIC PHARMACEUTICAL  
ASSOCIATION; BIOTECHNOLOGY  
INDUSTRY ORGANIZATION; and  
CONSUMER HEALTHCARE  
PRODUCTS ASSOCIATION,

Plaintiffs,

v.

KING COUNTY, WASHINGTON; KING  
COUNTY DEPARTMENT OF PUBLIC  
HEALTH; and DIRECTOR OF THE KING  
COUNTY DEPARTMENT OF PUBLIC  
HEALTH,

Defendants.

No. 2:13-cv-2151

COMPLAINT FOR  
DECLARATORY AND  
INJUNCTIVE RELIEF

The Pharmaceutical Research and Manufacturers of America, the Generic  
Pharmaceutical Association, the Biotechnology Industry Organization, and the Consumer  
Healthcare Products Association, by and through their undersigned attorneys, allege as  
follows:

**INTRODUCTION**

1. This is an action challenging King County’s “Secure Medicine Return Rule  
& Regulation” (the “Regulation”), a measure adopted by the King County Board of  
Health in June 2013 to establish “a county-wide secure medicine return program

1 providing equitable access for all of the county’s residents that is financed and operated  
2 by drug producers selling medicines in or into King County for residential use.”

3 2. The Regulation seeks to “place the obligation of complying with its  
4 requirements upon drug producers.” Indeed, the Regulation is explicit that it is “not  
5 intended to impose any duty whatsoever upon King County or any of its officers or  
6 employees.” What is more, the Regulation is accompanied by an express finding that  
7 King County seeks “to shift from a system focused on government-funded and ratepayer-  
8 financed waste disposal and diversion” toward a system funded by pharmaceutical  
9 producers.

10 3. In obligating all drug manufacturers whose products are sold in the County  
11 to establish local drug take-back programs, the Regulation conscripts parties engaged in  
12 interstate trade to implement what would otherwise be a local governmental function. It  
13 would shift costs of waste disposal from local taxpayers and/or local consumers to  
14 consumers located in other regions of the county. Far from fulfilling its responsibility to  
15 promote health and welfare within its territorial jurisdiction, King County is attempting to  
16 shift governmental responsibilities onto interstate businesses and local costs onto out-of-  
17 state consumers.

18 4. The Regulation represents a per se violation of the Commerce Clause for  
19 three principal reasons. First, it impermissibly directly regulates and burdens interstate  
20 commerce because it transfers a governmental responsibility onto pharmaceutical  
21 producers simply for placing their products in the stream of interstate commerce. Second,  
22 the Regulation has the impermissible primary purpose and clear effect of shifting costs of  
23 a local regulatory program directly onto interstate commerce and unrepresented out-of-  
24 county consumers. Finally, the Regulation has an impermissible extraterritorial effect by  
25 regulating entities with no significant ties to King County and by directly controlling  
26 conduct across county lines.



**PARTIES**

1  
2 10. Plaintiff Pharmaceutical Research and Manufacturers of America  
3 (“PhRMA”) is a non-profit organization representing pharmaceutical research and  
4 biotechnology companies that produce brand-name drugs. In bringing this lawsuit,  
5 PhRMA seeks to vindicate the interests of its members, who are subject to King County’s  
6 authority, and are being injured by the Regulation. The individual members themselves  
7 are not indispensable to proper resolution of the case.

8 11. Plaintiff Generic Pharmaceutical Association (“GPhA”) is a non-profit  
9 organization representing the manufacturers and distributors of finished generic  
10 pharmaceutical products. In bringing this lawsuit, GPhA seeks to vindicate the interests  
11 of its members, who are subject to King County’s authority and are being injured by the  
12 Regulation. The individual members themselves are not indispensable to proper resolution  
13 of the case.

14 12. Plaintiff Biotechnology Industry Organization (“BIO”) is a non-profit  
15 organization representing the manufacturers and distributors of biotechnology products.  
16 In bringing this lawsuit, BIO seeks to vindicate the interests of its members, who are  
17 subject to King County’s authority and are being injured by the Regulation. The  
18 individual members themselves are not indispensable to proper resolution of the case.

19 13. Plaintiff Consumer Healthcare Products Association (“CHPA”) is a non-  
20 profit organization representing leading manufacturers and marketers of over-the-counter  
21 medicines and dietary supplements. In bringing this lawsuit, CHPA seeks to vindicate the  
22 interests of its members, who are subject to King County’s authority and are being injured  
23 by the Regulation. The individual members themselves are not indispensable to proper  
24 resolution of the case.



1 collection sites and sorting and processing facilities will be significant and, regardless of  
2 the precautions taken, some level of theft, diversion and improper use will inevitably  
3 occur. The disposal of unwanted medicines in household waste eliminates the problem of  
4 “reconcentration” and reduces the likelihood of theft, diversion and improper use.

## 5 **II. The Regulation**

6 19. The King County Board of Health enacted the Regulation on June 20,  
7 2013.

8 20. The Regulation requires each covered drug manufacturer whose drugs are  
9 sold or distributed in King County to develop and submit a plan to take back unwanted  
10 drugs stored in residential homes. Under the Regulation, every covered drug  
11 manufacturer whose products reach King County must run, or contribute to, a privately  
12 administered drug take-back program.

13 21. The term “Covered drug” is defined to include any “drug sold in any form  
14 and used by” King County residents, “including prescription, nonprescription, brand name  
15 and generic drugs.” Regulation § 5(B)(1). The Regulation then excludes a number of  
16 items from the definition of “Covered drug.” The list of exclusions includes: all vitamins,  
17 herbal remedies, cosmetics, soap, detergent, drugs “for which producers provide a  
18 pharmaceutical product stewardship or take-back program as part of a federal food and  
19 drug administration managed risk evaluation and mitigation strategy,” drugs “that are  
20 biological products as defined by 21 C.F.R. 600.3(h) as it exists on the effective date of  
21 this rule if the producer already provides a pharmaceutical product stewardship or take-  
22 back program,” and “[m]edical devices, their component parts or accessories, or a covered  
23 drug contained in or on medical devices or their component parts or accessories.

24 Regulation § 5(B)(2).

25 22. The Regulation defines “Producer” as “a manufacturer that is engaged in  
26 the manufacture of a covered drug sold in or into King County, including a brand-name or

1 generic drug.” Regulation § 5(P). The Regulation then lists three exclusions from the  
2 definition of Producer. These exclusions apply to certain “retailer[s] whose store label  
3 appears on a covered drug or the drug’s packaging,” “pharmacist[s] who compounds a  
4 prescribed individual drug product for a consumer,” and any “wholesaler who is not also a  
5 manufacturer.” *Id.*

6 23. The Regulation provides that no Producer or other persons may “charge a  
7 specific point-of-sale fee to consumers to recoup the costs of their stewardship plan, nor  
8 may they charge a specific point-of-collection fee at the time the covered drugs are  
9 collected from covered entities.” Regulation § 11(C).

10 24. The Regulation obligates each Producer to operate either a “standard”  
11 comprehensive drug collection program, or an “independent” program approved by the  
12 Director. *See* Regulation § 6 (“Each producer shall participate in the standard stewardship  
13 plan approved by the director, except that a producer may individually, or with a group of  
14 producers, form and participate in an independent stewardship plan if approved by the  
15 director.”). Producers must inform the Director of their intent to establish a collection  
16 program within six months of either the Regulation’s adoption or “by six months after a  
17 producer initiates sale of a covered drug in or into King County.” Regulation § 6(C). At  
18 that point, Producers have three additional months to identify a “plan operator” and six  
19 months to propose a plan for the Director to approve. *See* Regulation § 6(D).

20 25. Producers must “pay all administrative and operational costs related to” the  
21 collection programs they must establish. Regulation § 11(A). These costs include:  
22 “[c]ollection and transportation supplies for each drop-off site, “[p]urchase of all secure  
23 drop boxes for drop-off sites in any independent stewardship plan,” “[o]ngoing  
24 maintenance or replacement of secure drop boxes, as requested by collectors,” “[p]repaid,  
25 preaddressed mailers provided to differentially-abled and home bound residents, and to  
26 specific areas of the county if utilized,” “[o]perating periodic collection events if utilized,

1 including costs of law enforcement staff time if necessary,” “[t]ransportation of all  
2 collected pharmaceuticals to final disposal, including costs of law enforcement escort if  
3 necessary,” “[e]nvironmentally sound disposal of all collected pharmaceuticals,” and  
4 “program promotion.” *Id.*

5 26. Producers “shall ensure the provision of up to four hundred secure drop  
6 boxes for retail pharmacies and law enforcement agencies willing to participate as drop-  
7 off sites for the standard stewardship plan.” *See* Regulation § 11(C).

8 27. When a retail pharmacy or law enforcement agency requests to serve as a  
9 collection site, Producers have three months to include those entities as collection  
10 locations. Regulation § 8(D)(2).

11 28. Producers “shall provide in every city, town, or unincorporated community  
12 service area with a pharmacy or law enforcement facility, one drop-off site and a  
13 minimum of at least one additional drop-off site for every thirty thousand residents,  
14 geographically distributed to provide reasonably convenient and equitable access.”  
15 Regulation § 8(D)(3). Other areas “shall be served through periodic collection events or  
16 mail-back services, or a combination of these collection methods.” *Id.* § 8(D)(4). “Mail-  
17 back services shall be free of charge.” *Id.* § 8(F).

18 29. Producers must “[p]romote the use of their stewardship plan so that  
19 collection options for covered drugs are widely understood by residents,” including by  
20 establishing “a toll-free telephone number and web site.” Regulation § 9(A).

21 30. Collected medicines “must be disposed of at a permitted hazardous waste  
22 disposal facility” in compliance with federal regulations, unless the Director grants special  
23 permission pursuant to specified procedures.

24 31. Collection plans approved by the Director must include a “list of all  
25 collection methods and participating collectors, a list of drop-off locations, a description  
26 of how periodic collection events will be scheduled and located if applicable, a description



1 of how mail-back services will be provided and an example of the prepaid, preaddressed  
2 mailers to be utilized.” Regulation § 7(B). Plans must also include a “description of the  
3 handling and disposal system, including identification of and contact information for  
4 collectors, transporters and waste disposal facilities to be used.” *Id.* § 7(C).

5 32. Plans are due one year after the Regulation’s adoption. Regulation §  
6 14(A). In reviewing plan submissions, the Director will allow for public comment. *Id.* §  
7 14(B). Within ninety days of receiving a plan submission, the Director will either approve  
8 or reject the submission. *Id.* § 14(C). If the plan is rejected, then the Producers will have  
9 sixty days to submit a revised plan. *Id.* § 14(D). If the revised plan is also rejected, then  
10 the Producers are considered out of compliance. *Id.* § 14(E). The Regulation contains no  
11 specific criteria for approving or disapproving a plan.

12 33. “A producer not participating in the standard stewardship plan or an  
13 independent stewardship plan and whose covered drug continues to be sold in or into the  
14 county sixty days after receiving a written warning from the director may be assessed a  
15 penalty.” Regulation § 14(C). If the Director finds a Producer to be out of compliance,  
16 the Director may transmit a written warning, at which point the Producer has thirty days to  
17 achieve compliance. *Id.* § 16(C).

18 34. The Director may charge a civil penalty of up to \$2,000 for any violation.  
19 Regulation § 16(D). “Each day upon which a violation occurs or is permitted to continue  
20 constitutes a separate violation.” *Id.*

### 21 **III. Plaintiffs’ Efforts to Comply With the Regulation**

22 35. Plaintiffs and their respective members have incurred, and will continue to  
23 incur, substantial compliance costs. The Regulation requires Plaintiffs’ members to enter  
24 into a new form of business—a combination of municipal waste disposal and local law  
25 enforcement. Plaintiffs, their members, and their employees are expending considerable  
26 resources and time to develop and submit a plan that complies with the Regulation, and

1 will continue to expend considerable resources and time to operate the required take-back  
2 programs. In addition, operation of the required collection programs will subject  
3 Plaintiffs, their members, and their employees to substantial liability risk.

4 **COUNT I**

5 **(Violation of the Commerce Clause)**

6 36. Plaintiffs reallege and incorporate by reference the allegations contained in  
7 all of the preceding paragraphs as though set forth fully herein.

8 37. The Constitution affords the federal government authority to “regulate  
9 commerce . . . among the several states.” U.S. Const. art. I, § 8. The constitutional  
10 framers adopted this provision in order to prevent local governments from imposing self-  
11 serving regulations that burden interstate trade for parochial purposes.

12 38. In its “negative” or “dormant” aspect, the Commerce Clause by its own  
13 force prohibits certain local regulations that discriminate against or burden interstate  
14 commerce. Local laws violate the Commerce Clause on a per se basis when they directly  
15 burden or regulate interstate commerce, discriminate against interstate commerce, or favor  
16 local interests. Local measures also violate the Commerce Clause when they levy unfairly  
17 apportioned taxes on interstate trade or impose excessive burdens on interstate commerce.

18 39. The Regulation does not improve or promote public health, but merely  
19 shifts King County’s public health responsibilities for waste disposal to private parties  
20 engaged in interstate commerce. The only purpose and effect of this measure is to shift  
21 costs away from local government, local consumers, and local taxpayers.

22 40. The Regulation represents a per se violation of the Commerce Clause for  
23 three principal reasons. First, the Regulation impermissibly directly regulates and burdens  
24 interstate commerce by transferring the County’s traditional police power responsibility of  
25 waste disposal to interstate actors solely on the basis that one of their products is sold in  
26 King County after being delivered there through an interstate distribution chain. Second,

1 the Regulation has the impermissible primary purpose and effect of burdening interstate  
2 commerce for local advantage by shifting costs and responsibilities of a local regulatory  
3 program away from local consumers and taxpayers and directly onto entities identified by  
4 their participation in interstate commerce. Because the Regulation prohibits charging fees  
5 to recoup the costs of the take-back program, out-of-county consumers will necessarily  
6 have to pay for a program that serves only King County residents. Finally, the Regulation  
7 has impermissible extraterritorial effect by reaching entities with no significant connection  
8 to King County and by compelling conduct across county lines.

9 41. The Regulation can also be viewed as an unconstitutional tax that violates  
10 the Commerce Clause. As noted above, the Regulation directly regulates and burdens  
11 interstate trade, applies extraterritorially, lacks any meaningful relation to regulated  
12 entities' connection to the County, and favors local interests. In addition, the Regulation  
13 imposes burdens that are not fairly apportioned and so creates a risk of duplicative  
14 regulatory burdens.

15 42. The Regulation further represents a per se violation of the Commerce  
16 Clause because it discriminates against interstate commerce and favors local interests.  
17 Under the Regulation, the entire burden of operating local collection efforts is borne by  
18 entities engaged in interstate commerce, while local constituents are deliberately and  
19 explicitly shielded from regulatory burdens.

20 43. The Regulation also violates the Commerce Clause because it imposes  
21 excessive burdens on interstate trade, despite the availability of less burdensome  
22 alternatives. King County could plainly achieve its environmental and health objectives  
23 by levying a conventional sales tax and implementing its own take-back program.  
24 Furthermore, disposal of unwanted pharmaceuticals in home garbage offers a safe,  
25 environmentally sound, and convenient alternative solution that does not burden  
26 significant and additional burdens on interstate commerce.

**COUNT II**

**(Violation of 42 U.S.C. § 1983)**

1  
2  
3 44. Plaintiffs reallege and incorporate by reference the allegations contained in  
4 all of the preceding paragraphs as though set forth fully herein.

5 45. 42 U.S.C. § 1983 provides a civil cause of action to any person who is  
6 deprived of rights guaranteed by the U.S. Constitution or federal laws by another under  
7 color of State law.

8 46. Defendants, acting under color of state and local law, and through their  
9 enactment, threatened enforcement, and enforcement of the Regulation as alleged herein,  
10 have deprived Plaintiffs and their members of their rights under the Commerce Clause of  
11 the U.S. Constitution.

12 47. Pursuant to 28 U.S.C. § 2201 and 42 U.S.C. § 1983, Plaintiffs and their  
13 members are therefore entitled to a declaration that Defendants, by their enactment,  
14 threatened enforcement, and enforcement of the Regulation, have violated the rights of  
15 Plaintiffs and their members under the Commerce Clause of the U.S. Constitution.

16 48. Pursuant to 42 U.S.C. § 1983, Plaintiffs and their members are further  
17 entitled to preliminary and or permanent injunctive relief, prohibiting Defendants or any  
18 other King County officers, employees, or agents from enforcing or threatening to enforce  
19 the Regulation against Plaintiffs and their members.

20 49. As a further result of Defendants' violation of the rights of Plaintiffs and  
21 their members as alleged herein, Plaintiffs are entitled to an award of their attorneys' fees  
22 pursuant to 42 U.S.C. § 1988.

**PRAYER FOR RELIEF**

23  
24 Wherefore, Plaintiffs pray for the following relief:

25 1. A declaration, order and judgment that the Regulation violates the Commerce  
26 Clause of the U.S. Constitution;

